KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Accumulated Expenses (2016 - 2026)

Amgen has reported Accumulated Expenses over the past 18 years, most recently at $16.6 billion for Q1 2026.

  • For Q1 2026, Accumulated Expenses fell 3.78% year-over-year to $16.6 billion; the TTM value through Mar 2026 reached $16.6 billion, down 3.78%, while the annual FY2025 figure was $18.5 billion, 5.0% up from the prior year.
  • Accumulated Expenses for Q1 2026 was $16.6 billion at Amgen, down from $18.5 billion in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $18.5 billion in Q4 2025 and troughed at $10.5 billion in Q2 2022.
  • A 5-year average of $14.4 billion and a median of $14.2 billion in 2023 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: surged 30.09% in 2023 and later dropped 3.78% in 2026.
  • Year by year, Accumulated Expenses stood at $12.5 billion in 2022, then rose by 22.64% to $15.4 billion in 2023, then rose by 14.86% to $17.6 billion in 2024, then rose by 5.0% to $18.5 billion in 2025, then fell by 10.47% to $16.6 billion in 2026.
  • Business Quant data shows Accumulated Expenses for AMGN at $16.6 billion in Q1 2026, $18.5 billion in Q4 2025, and $16.8 billion in Q3 2025.